



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



AMTB

Item No. 25336

CAS Registry No.: 926023-82-7
Formal Name: N-(3-aminopropyl)-2-[(3-methylphenyl)methoxy]-N-(2-thienylmethyl)-benzamide, monohydrochloride
MF: C₂₃H₂₆N₂O₂S • HCl
FW: 431.0
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AMTB is supplied as a solid. A stock solution may be made by dissolving the AMTB in the solvent of choice. AMTB is soluble in the organic solvent DMSO, which should be purged with an inert gas. It is also soluble in water. The solubility of AMTB in DMSO and water is approximately 100 mM. We do not recommend storing the aqueous solution for more than one day.

Description

AMTB is an antagonist of transient receptor potential melastatin 8 (TRPM8).¹ It inhibits calcium influx induced by the TRPM8 agonist icilin (Item No. 10137) with an IC₅₀ value of 0.58 μM. AMTB (3 mg/kg) decreases the number of volume-induced bladder contractions in a rat model of noxious bladder distension. It also decreases the visceromotor reflex response to urinary bladder distension (ID₅₀ = 2.42 mg/kg), indicating antinociceptive activity. AMTB inhibits the sodium channel (Na_v) isoforms Na_v1.1-1.8 (IC₅₀s = 2-14.8 μM) and decreases viability of MDA-MB-231 and SK-BR-3 breast cancer cells (IC₅₀s = ~23.7 and 17.3 μM, respectively) in a TRPM8-independent manner.²

References

1. Lashinger, E.S.R., Steingang, M.S., Hieble, J.P., *et al.* AMTB, a TRPM8 channel blocker: Evidence in rats for activity in overactive bladder and painful bladder syndrome. *Am. J. Physiol. Renal Physiol.* **295**(3), F803-F810 (2008).
2. Yapa, K.T.D.S., Deuis, J., Peters, A.A., *et al.* Assessment of the TRPM8 inhibitor AMTB in breast cancer cells and its identification as an inhibitor of voltage gated sodium channels. *Life Sci.* **198**, 128-135 (2018).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/09/2018

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM